Sign Up

Accessibility Policy

Accessibility Policy

Vanda Pharmaceuticals Inc. creates websites that are accessible to people with disabilities. This one has been designed to help educate people about HETLIOZ® (tasimelteon), and it is intended for patients with Non-24-Hour Sleep-Wake Disorder the majority of whom are totally blind—as well as their family, friends, doctors, and caregivers.

This website complies with all three levels of the World Wide Web Consortium (W3C) Web Access Initiative Guidelines and Recommendations for Content and Authoring Tools. We support and comply with AFB's "Policy Statement for Assuring That Materials Produced by the American Foundation for the Blind Are Accessible to People Who Are Blind or Visually Impaired."

This website was created to provide the easiest possible access for people who are blind, with visuals adapted for sighted people. It includes enhancements that promote accessibility and usability for blind or visually impaired users.

In its policies and its activities, Vanda asserts that all websites should be accessible to people with disabilities, and we urge all web developers to create sites that are accessible to all.

Though this site includes links to other websites, we cannot guarantee that they comply with web accessibility standards. If you find web accessibility problems, please contact each website's owners and ask that they comply with accessibility recommendations.

Any claims arising in connection with your use of this site or any Content or any Service must be brought within one (1) year of the date of the occurrence of the event giving rise to such action.

We appreciate any and all feedback. Please contact us at accessibility@vandapharma.com or call 1-844-HETLIOZ (1-844-438-5469) Monday through Friday from 9 AM to 8 PM, Eastern Standard Time.

Here's Important Safety Information for
HETLIOZ® (tasimelteon).

Indications

HETLIOZ® (HeT-lee-ōz) [tasimelteon] capsules are indicated for the treatment of:

  • Non-24-Hour Sleep-Wake Disorder (Non-24) in adults
  • Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) patients 16 years of age and older.

HETLIOZ LQ® (HeT-lee-oz el-Cue) oral suspension is indicated for:

  • Nighttime sleep disturbances in SMS in pediatric patients 3 to 15 years of age.

Important Safety Information

HETLIOZ® may cause drowsiness. After taking HETLIOZ®, limit your activity to preparing for bed. HETLIOZ® can potentially impair your ability to perform activities that require complete mental alertness.

The most common side effects associated with HETLIOZ® include headache, elevated liver enzymes (ALT), nightmares or abnormal dreams, and upper respiratory or urinary tract infection. These side effects may occur more frequently in patients 65 years of age or older. Adverse reactions were similar in patients treated for (Non-24) and patients with SMS treated for nighttime sleep disturbances. Adverse reactions were also similar in pediatric patients (3 years to 15 years) who received HETLIOZ LQ® oral suspension, and patients ≥16 years of age who received HETLIOZ® capsules.

Tell your healthcare provider about all of the medicines you're taking. HETLIOZ® should not be taken in combination with fluvoxamine or rifampin.

Tell your healthcare provider about all of your health conditions, including whether you are pregnant, are planning to become pregnant, or are breastfeeding. HETLIOZ® has not been studied in pregnant women.

The safety and effectiveness of HETLIOZ® for the treatment of Non-24-Hour in children have not been established. The safety and effectiveness of HETLIOZ LQ® oral suspension for the treatment of nighttime sleep disturbances in SMS have been established in pediatric patients 3 years and older.

HETLIOZ® is not recommended for use in patients with severe liver problems.

Consumer Important Safety Information

You are encouraged to report side effects of prescription drugs to the FDA. To report side effects, contact Vanda Pharmaceuticals Inc. at 1-844-438-5469 or www.hetlioz.com or FDA at 1-800-FDA-0178 or www.fda.gov/medwatch.

For more information, ask your healthcare provider or call 1-844-HETLIOZ (1-844-438-5469).

This information does not take the place of talking with your healthcare provider for medical advice about your condition or treatment.

Download an accessible PDF or listen to the full US Prescribing Information. You can also hear the full US Prescribing Information by calling 1-844-HETLIOZ (1-844-438-5469).